Zhejiang's new regulations on drug procurement are tough to reduce prices, and the large number of drug users, such as traditional Chinese medicine injection and antibacterial drugs, may suffer heavy losses

Source: asidake news agency, January 15, 2015, Zhejiang Pharmaceutical Machinery Procurement Center issued the second batch of centralized drug procurement implementation plan of the province yesterday for comments, in order to conduct public bidding for the first batch of drugs out of the procurement catalogue in the way of transaction price confirmation Big smart News Agency (wechat: DZH News) found that the price reduction of this Zhejiang drug collection bidding was more powerful than that of the first batch On the basis of setting a 10% price reduction threshold, the price of traditional Chinese medicine injections, antibacterial drugs and the top 200 varieties of distribution was reduced again or even cumulatively; At the same time, in addition to accepting the price reduction, drug manufacturers have almost no voice If they agree, they will win the bid, and if they disagree, they will lose their qualification In September last year, Zhejiang Province began to purchase the first batch of drugs, including 520 base drug catalog, Zhejiang basic drug catalog, low-cost drug catalog and drug catalog in short supply The implementation plan for 2014 drug centralized purchase (the second batch) in Zhejiang Province (Draft for comments) released this time is the centralized purchase of online trading products on the purchase platform of Zhejiang Province, except for the first batch of catalog varieties, cheap drugs, refined release varieties of poisonous and anesthetics, etc The focus of this centralized purchase is still on the price of drugs Although Zhejiang has made clear the price reduction in the first batch of centralized purchase, the price reduction of the second batch of drugs still surprises the market For all the drugs in the catalogue, the reference price I shall be the online transaction price decrease of 10% in the provincial procurement platform, among which for those belonging to traditional Chinese medicine injection or antibacterial drugs, the reference price I shall be reduced by 5%; It belongs to the top 200 varieties of distribution amount in 2013 On the basis of reference price I, the top 50 varieties will be reduced by 5%, 51-100 varieties will be reduced by 4%, 101-150 varieties will be reduced by 3%, 151-200 varieties will be reduced by 2% In particular, it should be noted that at the same time, the cumulative reduction calculated in line with the above two situations, that is to say, the cumulative maximum reduction will be 20% According to the previously published top 200 distribution amount in 2013 in Zhejiang Province, Xiyanping injection, a traditional Chinese medicine injection, is ranked in the top 50 distribution amount, which is in line with two situations, with a cumulative decrease, and the final decrease will reach 20% It is worth noting that in the first batch of centralized purchase of drugs, those ranked in the top 50 in the amount of distribution, such as Xueshuantong of Zhongheng group (600252 SH), Danhong injection of Bubu group, Shenqifuzheng injection of Lizhu group (000513 SZ) and other traditional Chinese medicine injections, also had significant pressure of price reduction In addition, Zhejiang adopts the way of drug transaction price confirmation this time, and no longer conducts the "double envelope" review For pharmaceutical enterprises, if they agree to supply the products of enterprises with reference price, they will be included in the scope of bid winning; if they disagree with the products, their online transaction qualification will be suspended, and the discourse right of pharmaceutical enterprises is almost zero Published by: Zhang Hua / Cao Minhui reviewed by: Shen Wei / Kang Yiyao